, Tracking Stock Market Picks
Enter Symbol:
Rating: MDC
Equal Weight $24
down 28.00 %

M.d.c. Holdings, Inc. (NYSE: MDC) reiterated to Equal Weight with price target $24 by Barclays

Wednesday,  Jan 20, 2016  2:25 PM ET by Kristen Bailey

The Barclays advised against investing in this stock and the price has fallen for a loss. The price fell from $28.34 on 10/13/2015 to $20.48 on 01/20/2016. Barclays reiterated M.d.c. Holdings,
Inc. (NYSE: MDC) to Equal Weight with price target $24 with today's price of $20.48. Barclays rated M.d.c. Holdings, Inc. (NYSE: MDC) to Overweight with price target $35 on 10/13/2015, when the price was $28.34. M.d.c. Holdings, Inc.'s stock price lost 28% since then.
By following the previous Barclays's recommendation on MDC, you would have lost 28% in 99 days.

Medicines Company acquires, develops and commercializes biopharmaceutical products in late stages of development. U.S. Food and Drug Administration intends to approve its first product, Angiomax, for use in the treatment ofpatients with unstable angina undergoing coronary balloon angioplasty. The company is also developing Angiomax for additional potential applications for use in the treatment of ischemic heart disease, a condition which occurs when organs receive an inadequate supply of oxygen as a result of decreased blood flow.


RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy